NIH researchers make AI tool to read cancer responses to immunotherapy
Researchers at the National Institutes of Health have developed an artificial intelligence tool that uses a simple blood test to predict if cancer.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Researchers at the National Institutes of Health have developed an artificial intelligence tool that uses a simple blood test to predict if cancer.
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
Negotiations at reaching a global accord to help fight pandemics better will conclude by 2025 or “earlier if possible at a special session.
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.
Eighteen million people are “acutely” hungry in conflict-ridden Sudan as a famine is on the horizon and 800,000 civilians get ready for large-scale.
Technology-based medical training has led to junior doctors avoiding the ward to stick to the electronic tablet — a healthcare crisis that will.
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
A dairy farm worker in Michigan, US, has been infected with highly pathogenic avian influenza from sick cows —the third such case in America.
Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)